tbuckley/cabot-search huggingface dataset:
Lurbinectedin (PM01183) administered once (D1) every 3 weeks (q3w) in combination with capecitabine (XEL) in patients (pts) with metastatic breast (MBC), colorectal (CRC) or pancreatic (PaC) cancer
Authors: T. Sauri, A. Awada, E. Calvo, V. Moreno, S. Szyldergemajn, E. Elez, P. Barthelemy, V. Boni, B. Doger, C. Fernandez Teruel, A. Soto-Matos, J. Tabernero, P. Aftimos
Journal: Annals of Oncology (2016)
Cytokeratin 4 is a novel predictive marker in early stage (T1/2) oral tongue squamous cell carcinoma (TSCC)
Authors: T. Enokida, S. Fujii, M. Takahashi, T. Wakasugi, T. Yamazaki, S. Okano, R. Hayashi, M. Tahara
Journal: Annals of Oncology (2016)
TMOD-22. SNAIL1 REGULATES GLIOMAGENESIS INDEPENDENT OF ITS MESENCHYMAL FUNCTION
Authors: Diem-Hang Nguyen-Tran, Mohamed Kabbout, Son Le, David Tran
Journal: Neuro-Oncology (2016)

Master mesenchymal factors such as SNAIL1 have long been implicated in local invasion and metastasis of various cancers including malignant brain tumors such as glioblastoma (GBM). However mesenchymal factors are expressed early in tumorigenesis, well before first evidence of metastatic cells, suggesting that these factors have other critical functions independent of their mesenchymal regulation. We used a highly penetrant, lentivirally-delivered, PDGFB-induced mouse model of gliomagenesis in a conditional PTEN and/or P53 knockout background to produce GBM tumors of the proneural subtype, in which SNAIL1 expression is much lower compared to the mesenchymal subtype. We then examined the effect of conditional KO of SNAIL1 in glial cells when PDGFB overexpression occurred, using in vitro and in vivo loss-of-function experiments augmented by RNAseq expression profiling and computational network analysis. SNAIL1 expression peaked early in gliomagenesis although its expression is downregulated once PDGFB-induced proneural tumors are formed. In an immune intact background, SNAIL1-null gliomas developed at a much slower pace. SNAIL1 cooperated with oncogene activity to promote higher transformative capacity and to influence the cancer stem cell compartment. Our data confirms a dual role for SNAIL1 in glioma progression, in which it cooperates with oncogenes to promote early transformation while independently also regulating mesechnymal changes at later stages of tumor development. Our platform combining RNAseq expression profiling and computational network analysis with biological validation provides a potentially powerful tool to study mechanistic events as low-grade gliomas become transformed into malignant gliomas.
Carcinoma of the ampulla of Vater: Patterns of failure after resection and benefit of adjuvant radiotherapy.
Authors: M. Palta, C. G. Willett, P. Patel, D. S. Tyler, H. E. Uronis, B. G. Czito
Journal: Journal of Clinical Oncology (2011)

254 Background: Ampullary carcinoma is a rare malignancy. Despite radical resection, survival rates remain low with high rates of local failure. To define the role of radiation therapy and chemotherapy with surgery, we performed a single institution analysis of treatment- related outcomes. Methods: A retrospective analysis was performed of all patients undergoing potentially curative therapy for adenocarcinoma of the ampulla of Vater at Duke University Hospitals between 1975 and 2009. Local control (LC), overall survival (OS), disease-free survival (DFS), and metastases-free survival (MFS) were estimated using the Kaplan-Meier Method. Results: One hundred thirty-seven patients with ampullary carcinoma underwent potentially curative pancreaticoduodenectomy. Sixty-one patients undergoing resection received adjuvant (n= 43) or neoadjuvant (n=18) radiation therapy with concurrent chemotherapy (CRT). Patients receiving radiotherapy were more likely to have poorly differentiated tumors. Median radiation dose was 50 Gy. Median follow up was 8.8 years. Of patients receiving neoadjuvant therapy, 67% were downstaged on final pathology with 28% achieving pathologic complete response. Three-year local control was significantly improved in patients receiving CRT (88% vs. 55% p= 0.001) with trend toward a 3-year OS benefit in patients receiving CRT (62% vs. 46% p=0.074). Despite this, there was no significant difference in 3-year DFS (66% CRT vs 48% surgery alone p=0.09) or MFS (69% CRT vs 63% surgery alone p=0.337). Conclusions: Long term survival rates are low. Local failure rates are high following radical resection alone and improved with CRT. Despite more adverse pathologic features in patients receiving CRT, survival outcomes were at least equivalent with a trend toward statistical significance. Given the patterns of relapse with surgery alone and local control benefit in patients receiving CRT, the use of chemoradiotherapy in selected patients should be considered. No significant financial relationships to disclose.
BCL6 Is Required for Leukemia-Initiation and Self-Renewal Signaling in Chronic Myeloid Leukemia.
Authors: Christian Hurtz, Cihangir Duy, Leandro Cerchietti, Eugene Park, Weimin Ci, Srividya Swaminathan, Soo-mi Kweon, Lars Klemm, Yong-mi Kim, Giovanni Martinelli, Wolf-Karsten Hofmann, B. Hilda Ye, Ari Melnick, Markus Müschen
Journal: Blood (2009)
A phase I dose-escalation trial of bi-daily (BID) weekly oral docetaxel as ModraDoc006 in combination with ritonavir
Authors: V.A. de Weger, F.E. Stuurman, M. Mergui-Roelvink, B. Nuijen, A.D.R. Huitema, J.H. Beijnen, J.H.M. Schellens, S. Marchetti
Journal: Annals of Oncology (2016)
The Gadd45 Family As Mediators of Hematopoietic Stem Cell Differentiation - from Genotoxic Stress to Cytokine-Induced Differentiation
Authors: Susanne Wingert, Frederic B Thalheimer, Nadine Haetscher, Maike Rehage, Hubert Serve, Timm Schroeder, Michael A. Rieger
Journal: Blood (2015)
Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis
Authors: J A Cutler, R Tahir, S K Sreenivasamurthy, C Mitchell, S Renuse, R S Nirujogi, A H Patil, M Heydarian, X Wong, X Wu, T-C Huang, M-S Kim, K L Reddy, A Pandey
Journal: Leukemia (2017)
Recreational Cannabis — Minimizing the Health Risks from Legalization
Authors: Beau Kilmer
Journal: New England Journal of Medicine (2017)

Interview with Dr. Beau Kilmer on the effects of cannabis on health and how jurisdictions can minimize harms related to its legalization. (08:57)Download Twenty percent of the U.S. population now lives in states that have passed ballot initiatives to allow cannabis to be sold for recreational use. The net effect of cannabis legalization on public health is uncertain, and much will depend on how the laws are implemented.
Presence of tumor-specific cytolytic T cells in human primary breast carcinoma: consequences for immunotherapy
Authors: D. Schröder, J. Carrasco, O. Bricard, G. Hames, N. Remy, K. Missault, J.-L. Canon, P. Vannuffel, C. Galant, M. Berlière, P.G. Coulie
Journal: Annals of Oncology (2016)
All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As2O3) Combination Therapy Induces High Rates of Durable Molecular Remission in Newly Diagnosed Acute Promyelocytic Leukemia (APL).
Authors: Apostolia-Maria Tsimberidou, Hagop Kantarjian, Susan O’Brien, Guillermo Garcia-Manero, Charles Koller, Daniel Jones, Sherry Pierce, Mark Brandt, Michael Keating, Estey Estey
Journal: Blood (2007)
NIMG-11. HIGHLY-EXPRESSED WILD-TYPE EGFR AND EGFRvIII MUTANT GLIOBLASTOMAS HAVE SIMILAR MRI SIGNATURE, CONSISTENT WITH DEEP PERITUMORAL INFILTRATION
Authors: Spyridon Bakas, Zev A. Binder, Hamed Akbari, Maria Martinez-Lage, Martin Rozycki, Jennifer J.D. Morrissette, Nadia Dahmane, Donald M. O’Rourke, Christos Davatzikos
Journal: Neuro-Oncology (2016)
Outcome of Umbilical Cord Blood Transplantation in 51 Patients with Hematologic Malignancies.
Authors: Zimin Sun, Huilan Liu, Liangquan Geng, Xingbing Wang, Xinchen Fang, Xin Liu, Huizhi Yang, Yongsheng Han, Weibo Zhu, Zuyi Wang
Journal: Blood (2009)
Is Stem Cell Transplantation for Transformed Follicular Lymphoma Required in the Rituximab Era?: The Royal Marsden Experience 2003-2013
Authors: Mary Gleeson, Eliza A Hawkes, Clare Peckitt, Andrew Wotherspoon, Ayoma Attygalle, Bhupinder Sharma, Yong Du, Mark Ethell, Michael Potter, Claire Dearden, Alan Horwich, Ian Chau, David Cunningham
Journal: Blood (2014)
Final Analysis of a Multicenter Pilot Phase 2 Study of Cytokine Induced Killer (CIK) Cells for Patients with Relapse after Allogeneic Transplantation
Authors: Federico Lussana, Martino Introna, Josee Golay, Federica Delaini, Chiara Pavoni, Ruth Valgarsddottir, Elisa Gotti, Alessandra Algarotti, Caterina Micò, Anna Grassi, Maria Chiara Finazzi, Irene Cavattoni, Adriana Balduzzi, Sara Napolitano, Attilio Rovelli, Giusi Sgroi, Paolo Perseghin, Giuseppe Gaipa, Ettore Biagi, Andrea Biondi, Alessandro Rambaldi
Journal: Blood (2016)
Subcutaneous Alemtuzumab May Be Useful in the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.
Authors: David Gomez-Almaguer, Guillermo J. Ruiz-Arguelles, Oscar Gonzalez-Llano, Homero C. Gutierrez-Aguire, Olga G. Cantu-Rodriguez, Jose C. Jaime-Perez, Sergio Giralt
Journal: Blood (2007)
A phase I dose escalation trial to assess the safety and preliminary efficacy of mFOLFOX6 combined with pembrolizumab (MK3475) in advanced gastrointestinal malignancies
Authors: D. Stenehjem, S. Gupta, M. Wade, G. Gilcrease, I. Garrido-Laguna, J.R. Weis, J. Whisenant, S. Sharma
Journal: Annals of Oncology (2016)
E2A-HLF Fusion Transcription Factor Mediating Aberrant Expression of LMO2 in B-Precursor ALL with t(17;19).
Authors: Kinuko Hirose, Takeshi Inukai, Koshi Akahane, Xiaochun Zhang, Itaru Kuroda, Hiroko Honna, Kumiko Goi, Toshiya Inaba, A. Thomas Look, Shinpei Nakazawa, Kanji Sugita
Journal: Blood (2006)
Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance
Authors: J. Riedl, F. Posch, M. Stotz, A. Bezan, T. Winder, R. Schaberl-Moser, M. Pichler, H. Stoeger, A. Gerger
Journal: Annals of Oncology (2016)
Clinical outcomes in patients age 40 or younger at diagnosis of synchonous metastatic colorectal cancer.
Authors: M. A. Lowery, D. J. Gallagher, N. E. Kemeny
Journal: Journal of Clinical Oncology (2011)

531 Background: The impact of age ≤ 40 at diagnosis of colorectal cancer on outcome is unclear. The higher incidence of tumor microsatellite instability (MSI) in young patients may confound the estimation of survival in this population due to the more favorable biology associated with MSI cancers. Methods: All pts diagnosed with metastatic colorectal adenocarcinoma at ≤ 40 years old between Jan 2000-Jan 2010 were identified from the institutional database with prior IRB approval. Clinical and pathology records were reviewed. Only patients with synchronous metastases at presentation were included. Immunohistochemistry for DNA mismatch repair proteins (MMR) was performed in 40 pts of whom 5 had loss of MMR and were excluded from the analysis. Results: 185 pts were identified; median age at diagnosis was 36 years (range 18–40) Primary site was in the right colon in 50 cases (27%). All pts received at least one line of systemic chemotherapy. For pts receiving systemic therapy median survival was 23.4 months and for those receiving hepatic arterial infusion (HAI) plus systemic the median survival was 48.2 months. Median survival for those who underwent liver resection (78 pts) was 54.6 months. Other factors such as race, post partum and KRAS mutation impacted on survival as shown below. Conclusions: Overall survival in this cohort of young pts is similar to that observed in clinical trials of modern combination therapy for metastatic CRC. African American race, presence of a KRAS mutation, and presentation following pregnancy may be associated with reduced survival in this group. [Table: see text] No significant financial relationships to disclose.
OS4.6 Large-scale radiomic profiling of recurrent glioblastoma identifies an imaging predictor for stratifying anti-angiogenic treatment response
Authors: P. Kickingereder, M. Götz, A. Wick, U. Neuberger, H. Schlemmer, A. Radbruch, W. Wick, M. Bendszus, K. Maier-Hein, D. Bonekamp
Journal: Neuro-Oncology (2016)
Mast Cells As a Therapeutic Target for Hodgkin Lymphoma: Bortezomib Inhibits Mast Cell-Induced Modification of the Tumor Microenvironment
Authors: Hiroki Mizuno, Takayuki Nakayama, Yasuhiko Miyata, Shigeki Saito, Nishiwaki Satoshi, Norihiko Nakao, Kyosuke Takeshita, Akihiro Tomita, Tomoki Naoe
Journal: Blood (2012)
Renal Heavy Chain and Heavy+Light Chain Amyloidosis: A Report of 17 Cases and Comparison with Renal Light Chain Amyloidosis
Authors: Samih H. Nasr, Samar M. Said, Anthony M. Valeri, Sanjeev Sethi, Lynn D. Cornell, Mary E. Fidler, Morie Abraham A Gertz, Angela Dispenzieri, Francis K Buadi, Julie A Vrana, Jason D Theis, Ahmet Dogan, Nelson Leung
Journal: Blood (2012)
QLIF-18. PATIENT EXPERIENCE THROUGH QUALITATIVE INTERVIEWS
Authors: Alvina A. Acquaye, Samuel S. Payén
Journal: Neuro-Oncology (2016)

Primary brain tumor (PBT) patients vary in their experience throughout the illness trajectory. The uncertainty that patients face has the potential to change how they cope with their diagnosis. This study used a triangulated approach to explore individual experiences with a PBT, and to explore themes related to symptom burden at diagnosis, during treatment and views of the future. Qualitative interviews and questionnaires were completed at patients clinic visit. Qualitative analysis of interviews was completed and number and severity of symptoms using the M.D. Anderson Symptom Inventory-Brain Tumor questionnaire was reported. The sample included 23 patients who were mostly female (52%), with glioblastoma (48%), currently on chemotherapy (48%), with a high KPS (79%) and mean age of 48. Patients reported an average 6.8 symptoms with 14% (mean=3) of symptoms reported as moderate to severe at the time of study. Themes related to experience before diagnosis including it being “traumatic or scary” with seizures and headaches commonly reported or less commonly a longer time with symptoms and being ‘misdiagnosed’. During treatment, fatigue, loss of hair and nausea were commonly reported symptoms impacting daily life activities and occurring with other symptoms but with type or pattern of symptoms related to the treatment received. In discussing the future, there were two themes of hope and positive impact with participants stating they “hope it goes away” and wanting to “just keep living”. A second theme of ‘feeling hopeless or grim’ was observed more in female patients (n=4), expressing “not making any future plans” and “it will probably be what kills me.” These findings offer a true insight from the patient’s perspective on the impact of symptoms throughout their illness. Future studies can focus on the comprehensive approach of patient care in managing their overall quality of life.
Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Pediatric Patients with Immune Thrombocytopenia (ITP)
Authors: Michael D Tarantino, James B. Bussel, Victor S. Blanchette, Jenny M. Despotovic, Carolyn Bennett, Ashok Raj, Bronwyn Williams, Donald Beam, Jaime Morales, Melissa J. Rose, Kun Nie, Melissa Eisen
Journal: Blood (2015)
A clinical trial of intradermal and intramuscular seasonal influenza vaccination in patients with atopic dermatitis
Authors: Donald Y.M. Leung, Brett Jepson, Lisa A. Beck, Jon M. Hanifin, Lynda C. Schneider, Amy S. Paller, Katherine Monti, Gloria David, Jennifer Canniff, Margarita Gomez Lorenzo, Adriana Weinberg
Journal: Journal of Allergy and Clinical Immunology (2017)
TMOD-31. AN INFLAMMATION RESPONSE GENE SIGNATURE IS ASSOCIATED WITH PROGNOSIS OF GLIOMA PATIENTS WITH 1p/19q CO-DELETION TUMORS
Authors: Xin Hu, Emmanuel Martinez-Ledesma, Siyuan Zheng, Hoon Kim, Floris Barthel, Tao Jiang, Kenneth R Hess, Roel Verhaak
Journal: Neuro-Oncology (2016)

Meta-analysis of glioma patients revealed that LOH of 1p/19q (IDH mutant-codel) is associated with favorable progression-free survival (PFS) and overall survival (OS). Heterogeneity in clinical outcomes exists within this subset of glioma. To determine transcriptional biomarkers associated with treatment response, we developed and independently validated a method to determine codel status using gene expression. We screened the transcriptional profiles from 1,828 gliomas to identify 333 cases predicted to harbor 1p/19 co-deletion. In order to identify a prognostic gene signature, we split this dataset into a training dataset (n=170) and a validation dataset (n=163) through random sampling. An elastic net penalized Cox’s proportional hazards model was applied to build a classifier model through cross validation within the training dataset. The performance of the gene signature was determined in the validation dataset, which showed that the gene signature was able to identify a high risk and a low risk subgroup with a significant difference in survival (p = 0.0065, Log-rank test). The predictive power of the gene signature using the concordance index was 0.65. For time to death events, the risk score predicted by the above genes signature yielded HR = 2.296 (95% confidence interval [CI] = 1.279 to 4.121) after adjustment for age and stratification for grade. Gene Set Variation Analysis revealed that inflammation response and acetylation activity were overrepresented amongst the signature genes. In summary, our study indicated that inflammatory associated factors are associated with clinical risk of glioma patients with 1p/19q CODEL, which could explain the different entity of clinical outcomes.
Phase II Study of Nivolumab (ONO-4538/BMS-936558) for Esophageal Cancer: Clinical activity by PD-L1 expression analysis
Authors: Hiroki Hara, Takashi Kojima, Shuichi Hironaka, Ken Kato, Takahiro Tsushima, Takashi Ura, Yuichiro Doki, Atsushi Ohtsu, Yasuo Hamamoto, Yuko Kitagawa
Journal: Annals of Oncology (2016)
The clinical values of methylation status of P16 and APC genes in bile in diagnosis of malignant obstructive jaundice.
Authors: X. Yin, G. Yan, J. Peng, L. Liang
Journal: Journal of Clinical Oncology (2011)

171 Background: Preoperative definitive diagnosis of malignant obstructive jaundice caused by biliary and pancreatic carcinomas still remains a major challenge. Hypermethylation of tumor suppressor genes have been implied in carcinogenesis of biliary and pancreatic malignancies. The diagnostic values of methylation status of tumor suppressor genes in bile in malignant obstructive jaundice have not been well-documented. Methods: Bile was prospectively collected from 70 patients with obstructive jaundice treated at our hospital between November 2008 and Sepetember 2009. Forty-eight of them were proved to be malignant obstructive jaundice (biliary carcinoma in 36, pancreatic carcinoma in 8 and duodenal carcinoma in 4) by pathological examination, and 22 were benign obstructive jaundice caused by cholelithiasis. DNA was extracted from bile and modified by sodium bisulfite. Methylation-specific PCR was run to detect methylation status of P16 and APC gene promoters. Their diagnostic values in malignant obstructive jaundice were assessed. Results: Hypermethylation of P16 promoter was presented in 72.9% (35/48) malignant obstructive jaundice, and 9% (2/22) bengin obstructive jaundice (p&lt;0.05). Hypermethylation of APC promoter was presented in 56.2% (27/48) malignant obstructive jaundice, and 9% (2/22) bengin obstructive jaundice (p&lt;0.05). With respect to their diagnostic values in malignant obstructive jaundice, sensitivity, specificity, positive predictivity and negative predictivity were 72.9%, 90.9%, 94.6% and 60.6%, respectively, for P16 gene; 56.2%, 90.9%, 93.1%, 48.8%, respectively, for APC gene. Conclusions: Methylation status of P16 and APC gene promoters in bile was valuable in diagnosis of malignant obstructive jaundice, with an excellent specificity. P16 gene had a higher sensitivity than APC gene. No significant financial relationships to disclose.
Impact on Outcomes of Baseline Bilirubin in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Receiving Defibrotide Treatment: A Post-Hoc Analysis
Authors: Paul G. Richardson, Angela R. Smith, Brandon M. Triplett, Nancy A. Kernan, Stephan A. Grupp, Joseph H. Antin, Leslie Lehmann, Wei Liang, Robin Hume, William Tappe, Robert J. Soiffer
Journal: Blood (2016)
Improved Outcome of Adult Acute Lymphoblastic Leukemia Treated with a Pediatric Protocol: Results of a Pilot Study.
Authors: Stephanie Haiat, Anne Vekhoff, Christophe Marzac, OrsAnton Calendini, Simona Lapusan, Zora Marjanovic, Bernard Rio, Jean-Pierre Marie, Ollivier Legrand
Journal: Blood (2007)
The potential of miR-630, an IGF1R regulator, as a predictive biomarker for HER2-targeted drugs.
Authors: Claire Corcoran, Sweta Rani, Susan Breslin, Irene M. Ghobrial, John Crown, Lorraine O'Driscoll
Journal: Journal of Clinical Oncology (2013)

620 Background: Innate or acquired resistance to current HER-targeting drugs indicates that their use for HER2-overexpressing breast cancer (BC) treatment may be compromised. miRNAs may have potential as diagnostic, prognostic and predictive biomarkers for treatment response, as well as therapeutic targets and replacement therapies. We aimed to investigate miR-630 as a predictive biomarker for response to a range of HER-drugs and as a potential target for increasing sensitivity to the same. Methods: Following global miRNA profiling using taqman low density arrays, the reduced expression of miR-630 in cells and corresponding conditioned medium (CM) of HER2-positive BC cell lines with acquired/innate lapatinib (L) resistance (SKBR3-LR, HCC1954-LR, MDA-MB-453) was confirmed by qPCR. miR-630 mimics and inhibitors were used to assess cell response to current (L, trastuzumab (T)) and emerging (neratinib (N), afatinib (A)) HER-targeting drugs. Targetscan prediction software and immunoblotting were used to determine miR-630 regulated proteins. Results: miR-630 levels were significantly decreased in cells and CM with acquired lapatinib resistance compared to their age-matched controls. Decreased miR-630 was also observed for innately resistant MDA-MB-453 compared to innately sensitive SKBR3.Administration of miR-630 mimic significantly sensitised resistant cells to all 4 drugs tested. Specifically, miR-630 mimic increased the anti-proliferative effects of L by 31% (SKBR3-LR), 9% (HCC1954-LR) and 9% (MDA-MB-453). Similarly, miR-630 mimic improved the efficacy of T (11-35%), N (4-17%) and A (9-25%); (range for different cell lines). Inhibition of miR-630 in sensitive parent cells induced an insensitive/resistant phenotype, significantly reducing the efficacy of all 4 drugs tested. Interestingly, miR-630 also significantly regulates cell motility, invasion and anoikis resistance implicating this miRNA in overall cell aggressiveness. Conclusions: This data suggests a potential role for miR-630 as a predictive biomarker for HER-targeting drugs as well as an additional therapeutic target for HER2-overexpressing BC. Acknowledgements: MTCI SFI SRC (08/SRC/B1410), MKF and HEA’s PRTLI Cycle 5 to TBSI.
Addition of Rituximab to CHOP Chemotherapy Does Not Improve Clinical Outcome in Patients with Localized Gastric Diffuse Large B-Cell Lymphoma: A Retrospective Study by Ganken Adult Lymphoma Study Group (Single Institute Analysis).
Authors: Masahiro Yokoyama, Daisuke Ennishi, Hiroaki Asai, Kyoko Ueda, Makoto Kodaira, Shuhei Yamada, Tomohiro Myojo, Yuko Mishima, Sakura Sakajiri, Kengo Takeuchi, Takashi Saotome, Yasuhito Terui, Shunji Takahashi, Yoshinori Ito, Kiyohiko Hatake
Journal: Blood (2007)
Pathogenetic Implications from the Analysis of Immunoglobulin Genes in Chronic Lymphocytic Leukemia of Mediterranean Ancestry: The Lesson of the IGHV3-21 Gene.
Authors: Paolo Ghia, Kostas Stamatopoulos, Chrysoula Belessi, Carol Moreno, Stefania Stella, Giuseppe Guida, Ariane Michel, Marta Crespo, Nikolaos Laoutaris, Emili Montserrat, Achilles Anagnostopoulos, Guillaume Dighiero, Athanasios Fassas, Federico Caligaris-Cappio, Frederic Davi
Journal: Blood (2004)